Abstract: The present invention relates to pyrazolopyrimidine derivatives having dual pharmacological activity towards both the ?2? subunit of the voltage-gated calcium channel and the sigma-1 (?1) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: A method for preparing a copper-containing catalyst is described comprising the steps of: (a) combining an acidic copper-containing solution with a basic precipitant solution in a first precipitation step to form a first precipitate, (b) combining an alkali metal aluminate solution with an acidic solution in a second precipitation step to form a second precipitate, (c) contacting the first and second precipitates together in a further precipitate mixing step to form a catalyst precursor, and (d) washing, drying and calcining the catalyst precursor to form the copper-containing catalyst, wherein at least 70% by weight of the copper in the catalyst is present in the first precipitate and a silica precursor is included in the first precipitation step, the second precipitation step or the precipitate mixing step, to provide a catalyst with a silica content, expressed as SiO2, in the range of 0.1 to 5.0 wt %.

Abstract: A process for the production of hydrogen is described, the process comprises the steps of: (a) generating a synthesis gas comprising hydrogen, carbon monoxide, carbon dioxide and steam in a synthesis gas generation unit; (b) increasing the hydrogen content of the synthesis gas and decreasing the carbon monoxide content by subjecting it to one or more water-gas shift stages in a water-gas shift unit to provide a hydrogen-enriched gas, (c) cooling the hydrogen-enriched gas and separating condensed water therefrom, (d) passing the resulting de-watered hydrogen-enriched gas to a carbon dioxide separation unit to provide a carbon dioxide gas stream and a hydrogen gas stream, wherein the synthesis gas from step (a) is fed without adjustment of the carbon monoxide content to a water gas shift reactor.

Abstract: A method for preparing a copper-containing catalyst is described comprising the steps of: (a) combining an acidic copper-containing solution with a first basic precipitant solution in a first precipitation step to form a first precipitate, (b) combining an acidic aluminium-containing solution, further comprising one or more metal compounds selected from copper compounds, zinc compounds and promoter compounds, with a second basic precipitant solution in a second precipitation step to form a second precipitate, (c) contacting the first and second precipitates together in a further mixing step to form a catalyst precursor, and (d) washing, drying and calcining the catalyst precursor to form the copper-containing catalyst, wherein a silica precursor is included in the first precipitation step, the second precipitation step or the precipitate mixing step, to provide a catalyst with a silica content, expressed as S102, in the range of 0.1 to 5.0 wt%.

Abstract: The present invention relates to homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having dual pharmacological activity towards both the ?2? subunit of the voltage-gated calcium channel and the sigma-1 (?1) receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: A catalyst suitable for use in carbon oxide conversion reactions is described, said catalyst in the form of a shaped unit formed from an oxidic catalyst powder, said catalyst comprising 30-70% by weight of copper oxide, combined with zinc oxide, alumina and silica, having a Si:AI atomic ratio in the range 0.005 to 0.15:1, and having a BET surface area >105 m2/g and a copper surface area >37 m2/g catalyst. The catalyst is prepared by a co-precipitation method using an alumina sol.

Abstract: A mixture having a poly(alkylene carbonate) and a non-polymeric organic molecule having a molecular weight below 1,000 Da may be used as a self-healing material. The non-polymeric organic molecules having a molecular weight below 1,000 Da may also be used to impart self-healing behaviour to a mixture having a poly(alkylene carbonate).

Abstract: A polyether carbonate polyol with a nominal functionality of 3 or more includes an equivalent molecular weight between 20,000 and 500,000 Da, and content of between 0.5 wt % and 35 wt % of CO2 based on the total weight of the polyether carbonate polyol. The polyether carbonate polyol has adhesive and impact modifying properties.

Abstract: The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to tetrahydropyran and thiopyran derivatives having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention refers to a formulation suitable for the manufacture of a pressure sensitive adhesive, said formulation comprising: a) 40-95 wt % of polyalkylene carbonate having a number average molecular weight higher than 17.000 Da; b) 5-60 wt % of a polyether carbonate polyol having CO2 groups randomly incorporated in the chemical structure thereof, wherein the content of CO2 ranges from 0.5 to 40 wt %, based on the total weight of the polyether carbonate polyol; and c) optionally, less than 30 wt % of a tackifying resin, provided that said formulation does not contain any reticulating agent.

Abstract: The present invention relates to tetrahydropyran and tetrahydrothiopyran amide derivatives having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: An adhesive composition comprising includes (i) a copolymer of an unsaturated hydrocarbon and an acrylate ester or acid, or of an unsaturated hydrocarbon and a vinyl saturated aliphatic ester or mixtures thereof, and (ii) a polyether carbonate polyol wherein the weight proportion of CO2 ranges from 0.5 to 37 wt % with respect to the total weight of the polyether carbonate polyol. The compositions of the invention may be used in PSA or HotMelt adhesive formulations.

Abstract: The present invention is directed to a polymer blend comprising at least one polyalkylencarbonate (PAC) and at least one polyhydroxyalkanoate (PHA) with low crystallinity. The invention also describes processes to prepare the blends of the invention and articles made of said blends.

Abstract: A polyether carbonate polyol with a nominal functionality of 3 or more includes an equivalent molecular weight between 20,000 and 500,000 Da, and content of between 0.5 wt % and 35 wt % of CO2 based on the total weight of the polyether carbonate polyol. The polyether carbonate polyol has adhesive and impact modifying properties.

Abstract: The present invention relates to substituted amide derivatives having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present invention relates to spiro-isoquinoline-1,4?-piperidine compounds having dual pharmacological activity towards both the sigma (?) receptor and the ?-opiod receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.